Patent 7144863 was granted and assigned to Eli Lilly and Company on December, 2006 by the United States Patent and Trademark Office.
The present invention encompasses compositions wherein a GLP-1 compound is complexed with a basic polypeptide. The compositions provide a prolonged duration of action and can be administered by the pulmonary route.